The ASX-listed investment manager smashed analysts’ expectations thanks to the stellar performance of its growth house.

Brooks Running has outpaced the crowded field of performance footwear thanks to its never-ending chase of perfection. Earlier ...

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

Enter NYXI with its updated Hyperion 2 Joy-Con pads, pitched as "the ultimate replacement" for the real Mc-Con. They don't ...

Brooks Running has a mega list of popular shoes on sale for less than $100. Shoppers can grab huge deals on shoes like the ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial ...

In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

Brooks Running often refreshes its markdown page but in a rare deal, the Hyperion is seeing a markdown as low as $84. Originally $140, shoppers can now get 40% off. Runners can track their pace wi ...

In close partnership with ALLIED Feather + Down (AF+D) and premium performance wear manufacturer Active Apparel Group, Templa ...